235 related articles for article (PubMed ID: 30167757)
1. Voriconazole greatly increases the exposure to oral buprenorphine.
Fihlman M; Hemmilä T; Hagelberg NM; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
Eur J Clin Pharmacol; 2018 Dec; 74(12):1615-1622. PubMed ID: 30167757
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.
Fihlman M; Hemmilä T; Hagelberg NM; Kuusniemi K; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
Eur J Clin Pharmacol; 2016 Nov; 72(11):1363-1371. PubMed ID: 27510521
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole drastically increases exposure to oral oxycodone.
Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
Bai SA; Xiang Q; Finn A
Clin Ther; 2016 Feb; 38(2):358-69. PubMed ID: 26804639
[TBL] [Abstract][Full Text] [Related]
6. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
[TBL] [Abstract][Full Text] [Related]
7. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
8. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl.
Saari TI; Laine K; Neuvonen M; Neuvonen PJ; Olkkola KT
Eur J Clin Pharmacol; 2008 Jan; 64(1):25-30. PubMed ID: 17987285
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole and fluconazole increase the exposure to oral diazepam.
Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
[TBL] [Abstract][Full Text] [Related]
10. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
[TBL] [Abstract][Full Text] [Related]
11. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
[TBL] [Abstract][Full Text] [Related]
12. Effect of voriconazole on the pharmacokinetics of diclofenac.
Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Laine K
Fundam Clin Pharmacol; 2007 Dec; 21(6):651-6. PubMed ID: 18034666
[TBL] [Abstract][Full Text] [Related]
13. Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system.
Kapil RP; Cipriano A; Michels GH; Perrino P; O'Keefe SA; Shet MS; Colucci SV; Noveck RJ; Harris SC
Clin Drug Investig; 2012 Sep; 32(9):583-92. PubMed ID: 22845044
[TBL] [Abstract][Full Text] [Related]
14. Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.
Grün B; Merkel U; Riedel KD; Weiss J; Mikus G
Br J Clin Pharmacol; 2012 Nov; 74(5):854-63. PubMed ID: 22381043
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
[TBL] [Abstract][Full Text] [Related]
16. Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.
Hagelberg NM; Fihlman M; Hemmilä T; Backman JT; Laitila J; Neuvonen PJ; Laine K; Olkkola KT; Saari TI
Pharmacol Res Perspect; 2016 Dec; 4(6):e00271. PubMed ID: 28097004
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.
Kharidia J; Howgate EM; Laffont CM; Liu Y; Young MA
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1064-1074. PubMed ID: 33750027
[TBL] [Abstract][Full Text] [Related]
18. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
Kuhlman JJ; Lalani S; Magluilo J; Levine B; Darwin WD
J Anal Toxicol; 1996 Oct; 20(6):369-78. PubMed ID: 8889672
[TBL] [Abstract][Full Text] [Related]
19. Itraconazole increases plasma concentrations of quinidine.
Kaukonen KM; Olkkola KT; Neuvonen PJ
Clin Pharmacol Ther; 1997 Nov; 62(5):510-7. PubMed ID: 9390107
[TBL] [Abstract][Full Text] [Related]
20. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.
Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Vyyryläinen H; Laine K
Antimicrob Agents Chemother; 2006 Jun; 50(6):1967-72. PubMed ID: 16723553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
